Upcoming Research Opportunities

We are hiring a postdoctoral researcher!
An exciting opportunity to join our new project on MRI-based imaging biomarker development in ALS. The appointment will be at the Center for Magnetic Resonance Research (CMRR) at the University of Minnesota. The CMRR is one of the world’s premier magnetic resonance imaging facilities, with considerable expertise in imaging physics, engineering, and clinical research. Further details and a formal application link are available at

https://hr.myu.umn.edu/jobs/ext/359206

CVs and/or informal inquiries about the position may be emailed to Pramod Pisharady at email hidden; JavaScript is required before submitting a formal application.

Call for Abstracts: ALS Nexus 2025 Poster Session

The ALS Association is currently accepting abstracts for its ALS Nexus 2025 Poster Session. This is a unique opportunity to share how your research is helping make ALS a livable disease with the diverse group of people who attend this conference. Established and early-career investigators, health care professionals, fellows, graduate students, and medical students are invited to submit an abstract by Tuesday, April 1, 2025, 5 p.m. ET. Abstracts should be no more than 250 words and include the hypothesis/objective, brief methods, results, and conclusion.

Please note that presenters of accepted posters are required to register for the ALS Nexus conference, which will be held August 11–14 in Dallas, Texas. The ALS Association does not have the funds available to pay for registration and/or travel expenses for poster presenters.

Learn more and submit your abstract: https://event.alsnexus.org/event/beb97dac-6eec-48f3-a4b6-a20a0939638f/poster-session.

Made possible by the AFTD Holloway Family Fund, the Alzheimer’s Association, and other partners

With support from the Holloway Family Fund, AFTD has partnered with the Alzheimer's Association to provide funding to researchers with promising, relevant research poised to advance our understanding of FTLD biomarkers. By supporting researchers, we and our partners hope to pave the path to more accurate and timely diagnosis for families affected by FTD.

Award Details

• Duration: up to 2 years
• Amount of award (USD): Budget requests between $250,000 - $700,000.
  Amount is dependent on stage of development and scope of project.
• Application of funds: All applications require a detailed budget and corresponding budget rationale included. Applicants from academic or non-profit institutions may request up to 10% of the approved budget be allocated to indirect costs.

Who Can Apply?

This funding opportunity is open to investigators worldwide at:

• Academic or other nonprofit research institutions
• For-profit organizations such as biotechnology or diagnostics companies

Collaborative arrangements, e.g., between academia and industry, senior and early-career researchers, or ALS and FTD researchers, are encouraged.

Postdoctoral researchers cannot apply as the lead Principal Investigator but can be co-PIs on a project team.

The AFTD is committed to increasing the diversity of the scientific workforce and encourage applications by researchers from underrepresented or historically excluded populations.

Timeline: 2025 FTD Biomarkers Initiative Grants

• Application submission portal opens: March 2025
• Application deadline: May 9, 2025
• Notification of awards: Late summer to early fall 2025
• Award start date: Within three months of award notification

Learn More Here.

The Harvard/Partners Neurodegeneration Clinical Research (NCR) Fellowship is designed to produce experts in the field of neurodegenerative diseases and clinical research, with a particular focus on the clinical care and research of neurodegenerative disease, who will shape clinical research in these fields throughout their career.

The Neurodegeneration Clinical Research Fellowship training will occur via two major avenues: 1) Clinical Care training conducted primarily through mentored clinical encounters and supplemented by clinical conferences and individual study; and 2) Clinical Research training conducted through the experience of acting as a sub-investigator on at least one non-interventional research project and at least one treatment trial, as well as the development of one unique clinical research project with the careful support of a research mentor.

Eligibility/Application Process

Candidates must be board-eligible in Neurology, have completed residency in good standing prior to the start of the fellowship, and have a strong interest in clinical research. Candidates may have completed a one year neuromuscular fellowship or equivalent prior to joining this fellowship.

For more information on the Neurodegenerative Clinical Research Fellowship, and how to apply, please view the fellowship website (https://www.mgbneurologyfellowships.org/fellowships/neurodegenerative.htmlcontact) and contact Program Director, email hidden; JavaScript is required.

MDA provides support for research throughout the pipeline of drug development from discovery research through clinical trials. Funding opportunities exist for both academic investigators as well as for biotech and pharma seeking to develop therapies for neuromuscular disease.

Learn about all our grant programs and find deadlines and instructions on how to apply.

Gupta Family Endowed Prize for Innovation in ALS Care

The Gupta Family Endowed Prize for Innovation in ALS Care is an annual global prize to honor ground-breaking new approaches that lead to exceptional care for individuals living with amyotrophic lateral sclerosis (ALS).

This annual prize is awarded to a nominated team that has developed promising new approaches to improving care for people living with ALS. Examples of ALS care

innovation include but are not limited to assistive technology, multidisciplinary care,

communication and education, trials, nutrition.

Nominations Due: Friday, May 30^th at 5pm EST

Presentation of award: NEALS Annual Meeting October 7-10, 2025

Award: $40,000 USD and travel reimbursement up to $2,500 USD to attend the Annual NEALS Meeting

To learn more about the 5^th annual prize and how to nominate a team, click here.

Advancing ALS Discovery through Artificial Intelligence and Natural Language Processing

Overview:

ALS Finding a Cure® is pleased to announce a Request for Proposals (RFP) to support innovative research projects leveraging Artificial Intelligence (AI) and Natural Language Processing (NLP) to advance ALS discovery. This funding opportunity seeks to catalyze transformative research that integrates AI-driven methodologies to improve diagnosis, biomarker identification, disease progression modeling, and therapeutic target discovery in ALS.

Background:

ALS is a devastating neurodegenerative disease with no cure and limited therapeutic options. AI and NLP offer the potential to revolutionize ALS research by enabling the extraction of meaningful insights from complex datasets, including electronic health records (EHRs), published medical literature, clinical trial data, omics datasets, and real-world patient-reported data. Through this RFP, we aim to support high-impact projects that will enhance our understanding of ALS and accelerate novel therapeutic strategies.

Examples of large data sources include but are not limited to:

Answer ALS, ALS Compute, UK Bio Bank. ProACT, NeuroBank, Project MINE, ALS TDI ARC, and other commercially available health record data

Scope of the RFP:

We invite applications proposing AI and/or NLP-based approaches to address critical challenges in ALS research. Areas of interest include, but are not limited to:

· Drug Discovery and Repurposing: Machine learning-based identification of potential ALS drug targets or repurposed therapies using AI-driven drug screening techniques.

· Biomarker Discovery and Validation: Integration of AI/NLP with multi-omics, imaging, and patient-reported outcomes to identify and validate ALS biomarkers.

· AI-Driven Early Diagnosis: Use of AI and NLP for automated extraction of early clinical features from EHRs, speech and language analysis, or fluid biomarker or imaging data to improve early detection of ALS.

· Pathomechanistic Knowledge Graphs: Integration of NLP tools with the published medical literature for discovery of previously underappreciated mechanistic targets.

· Disease Progression Modeling: AI-based analysis of longitudinal clinical and /or biomarker data to enhance prediction models for disease progression and stratification of patients.

· Optimizing Clinical Trials: AI-powered patient stratification, automated NLP-based extraction of clinical endpoints from records, virtual comparison groups and trial recruitment optimization.

· Data Subtypes: Use of AI technology to separate ALS from Controls and to find ALS subtypes in the Answer ALS data set by combining clinical, biomarker, genetic and motor neuron omics data.

Eligibility Criteria:

· Open to researchers at academic, medical, and research institutions worldwide.

· Multidisciplinary and collaborative proposals integrating AI/NLP expertise with ALS clinical or biological research are encouraged.

· Prior AI/NLP experience is not required, but partnerships with computational experts are recommended.

· Pharmaceutical & Clinical Collaboration: Synergistic collaboration between industry and institutions with data-driven models encouraged.

Funding and Award Information:

· Grant Duration: Up to 2 years

· Funding Amount: Up to $400,000 USD total (inclusive of both direct and indirect costs)

· Number of Awards: 3 awarded teams

· Indirect Costs: Maximum of 15%

Application Timeline:

· Initial Letter of Interest (LOI) Submission Due: Friday May 23, 2025

· Notification of LOI Submission: June 2025

· Full Proposals Due: Wednesday August 8, 2025

· Project Start Date: Wednesday October 1, 2025

Review Criteria:

Proposals will be evaluated based on:

1. Scientific Merit and Innovation: Potential of AI/NLP methodologies to transform ALS research.

2. Feasibility and Approach: Strength of study design, methodology, and data integration strategy.

3. Investigative Team: Expertise and collaborative potential of the research team.

4. Translational Potential: Likelihood of findings contributing to improved ALS diagnostics, treatments, or patient outcomes.

How to Apply:

Application Process

This will be a two-step process. Applicants will first submit a formal Letter of Interest. Selected applicants will then be asked to submit a full proposal if chosen.

1. First Step – Letter of Intent:

Letter of Intent should be max 2 pages in length and include the following:

o Proposal Title

o Team’s highlighted experience

o Brief overview of project

o Expected Outcomes

2. Second Step - Expanded Application

·If Letter of Interest is accepted, you will be asked to provide a cover letter

addressed to ALS Finding a Cure and the Leandro P. Rizzuto Foundation

including:

o Proposal Title

o Total costs (15% overhead cap)

o Number of milestones and related costs (to equal amount above)

o List of all investigators and institutions

o Name and contact information for person(s) responsible for contracts

o Address for mailing of payments

·Provide a study plan including:

o A brief abstract suitable for media release to the lay public if the application is successful

o Project Plan, Background, and Timeline (max. 5 pages) including:

· Study background and rationale/significance

· Study objectives/specific aims

· Supporting/preliminary data;

· Experimental design/research plan;

· Source of data and confirmation of access;

· Detailed itemized budget and budget justification

· Description of study milestones, including the costs associated and timeline of specific deliverables

· Any research funding from other funding sources that relates to the proposed work

·Signed and dated investigator CVs

·Financial Disclosure Form: use either NIH Form

https://ethics.od.nih.gov/forms450), or institutional form.

Submit LOI to: https://app.box.com/f/33b7d67838bb4bc987eb5e65686411ea

For more information on submission guidelines please see:

https://www.alsfindingacure.org/2025-als-finding-a-cure-request-for-proposals/

Please submit questions to email hidden; JavaScript is required

ALS Finding a Cure® is committed to supporting cutting-edge research that will drive meaningful advancements in ALS discovery through AI and NLP.